Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Ars Pharmaceuticals Inc (SPRY)

Ars Pharmaceuticals Inc (SPRY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,086,528
  • Shares Outstanding, K 97,185
  • Annual Sales, $ 30 K
  • Annual Income, $ -54,370 K
  • EBIT $ -61 M
  • EBITDA $ -67 M
  • 60-Month Beta 0.88
  • Price/Sales 36,671.14
  • Price/Cash Flow N/A
  • Price/Book 5.46

Options Overview Details

View History
  • Implied Volatility 85.40% ( -7.42%)
  • Historical Volatility 73.08%
  • IV Percentile 68%
  • IV Rank 58.70%
  • IV High 130.73% on 01/12/24
  • IV Low 20.97% on 06/10/24
  • Put/Call Vol Ratio 0.47
  • Today's Volume 893
  • Volume Avg (30-Day) 356
  • Put/Call OI Ratio 0.41
  • Today's Open Interest 13,975
  • Open Int (30-Day) 12,547

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.09
  • Number of Estimates 3
  • High Estimate 0.26
  • Low Estimate -0.27
  • Prior Year -0.07
  • Growth Rate Est. (year over year) -28.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.63 +5.17%
on 12/18/24
14.90 -24.97%
on 11/29/24
-2.37 (-17.49%)
since 11/20/24
3-Month
10.63 +5.17%
on 12/18/24
18.51 -39.60%
on 11/11/24
-3.59 (-24.31%)
since 09/20/24
52-Week
5.02 +122.71%
on 12/21/23
18.51 -39.60%
on 11/11/24
+6.14 (+121.83%)
since 12/20/23

Most Recent Stories

More News
ARS Pharmaceuticals’ neffy® Added to Express Scripts Commercial National Formularies, Enhancing Access for Allergy Patients

Neffy nasal spray included in Express Scripts formularies enhances access for patients with Type 1 allergic reactions.Quiver AI SummaryARS Pharmaceuticals, Inc. announced that neffy® (epinephrine nasal...

SPRY : 11.18 (-1.24%)
ARS Pharmaceuticals Announces neffy® (Epinephrine Nasal Spray) is available on Express Scripts Commercial National Formularies

SPRY : 11.18 (-1.24%)
ARS Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

SPRY : 11.18 (-1.24%)
Insider Sale: Chief Business Officer of $SPRY (SPRY) Sells 27,272 Shares

Justin Chakma, the Chief Business Officer of $SPRY ($SPRY), sold 27,272 shares of the company on 12-13-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 16.7%...

SPRY : 11.18 (-1.24%)
Insider Sale: Chief Business Officer of $SPRY (SPRY) Sells 50,000 Shares

Justin Chakma, the Chief Business Officer of $SPRY ($SPRY), sold 50,000 shares of the company on 12-10-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 26.8%...

SPRY : 11.18 (-1.24%)
ARS Pharmaceuticals' Licensing Partners File for Approval of neffy® 2 mg in China, Japan, and Australia

ARS Pharmaceuticals' neffy® nasal spray receives approval filings in China, Japan, and Australia for treating severe allergic reactions.Quiver AI SummaryARS Pharmaceuticals, Inc. announced that its licensing...

SPRY : 11.18 (-1.24%)
ARS Pharmaceuticals Announces Filings for Approval of neffy® in China, Japan and Australia

SPRY : 11.18 (-1.24%)
Insider Sale: CHIEF MEDICAL OFFICER of $SPRY (SPRY) Sells 50,000 Shares

Sarina Tanimoto, the CHIEF MEDICAL OFFICER of $SPRY ($SPRY), sold 50,000 shares of the company on 12-10-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 3.9%...

SPRY : 11.18 (-1.24%)
Insider Sale: Chief Business Officer of $SPRY (SPRY) Sells 45,000 Shares

Justin Chakma, the Chief Business Officer of $SPRY ($SPRY), sold 45,000 shares of the company on 12-03-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 24.8%...

SPRY : 11.18 (-1.24%)
Insider Sale: Director at $SPRY (SPRY) Sells 14,772 Shares

Laura Shawver, a director at $SPRY ($SPRY), sold 14,772 shares of the company on 12-04-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 6.6% of their shares....

SPRY : 11.18 (-1.24%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Average short term outlook on maintaining the current direction.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

ARS Pharmaceuticals Inc. is dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions which could lead to anaphylaxis. The company is developing neffy(TM) an intranasal epinephrine product in clinical development for patients and their caregivers...

See More

Key Turning Points

3rd Resistance Point 12.29
2nd Resistance Point 11.93
1st Resistance Point 11.55
Last Price 11.18
1st Support Level 10.82
2nd Support Level 10.46
3rd Support Level 10.08

See More

52-Week High 18.51
Fibonacci 61.8% 13.36
Fibonacci 50% 11.77
Last Price 11.18
Fibonacci 38.2% 10.17
52-Week Low 5.02

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar